Nothing Special   »   [go: up one dir, main page]

PE20060729A1 - Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina - Google Patents

Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina

Info

Publication number
PE20060729A1
PE20060729A1 PE2005000882A PE2005000882A PE20060729A1 PE 20060729 A1 PE20060729 A1 PE 20060729A1 PE 2005000882 A PE2005000882 A PE 2005000882A PE 2005000882 A PE2005000882 A PE 2005000882A PE 20060729 A1 PE20060729 A1 PE 20060729A1
Authority
PE
Peru
Prior art keywords
phenyl
imidazol
modulators
inhibitors
heterocyclic compounds
Prior art date
Application number
PE2005000882A
Other languages
English (en)
Inventor
David G Sawutz
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of PE20060729A1 publication Critical patent/PE20060729A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/132—Heterocyclic compounds containing only one nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/116—Heterocyclic compounds
    • A23K20/137—Heterocyclic compounds containing two hetero atoms, of which at least one is nitrogen
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
    • A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I), EN DONDE R1 ES H, NAFTILO O FENILO OPCIONALENTE SUSTITUIDO CON HALO, ALCOXI(C1-C6), ALQUILTIO(C1-C6), FENILO, ENTRE OTROS O R1 ES UN FENILO FUSIONADO CON UN HETEROCICLO OPCIONALMENTE AROMATICO, CON HASTA 2 HETEROATOMOS DE N, O Y S; R2 ES H O PIRIDINIL SUSTITUIDO CON R5; R3 ES CO2H, CONH2, CN, CONHOH, CH2OH, TETRAZOL, ENTRE OTROS; UNO DE X1 Y X2 ES N, S, O O CR8, Y EL OTRO ES NR8 O CHR8, DONDE R8 ES H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C7), O CUANDO UN X1 Y X2 ES N O CR8, ENTONCES EL OTRO ES S U O. SON PREFERIDOS: 4-[4-(4-FLUORFENIL)-5-(2-PIRIDIL)-1-HIDROXI-1H-IMIDAZOL-2-IL]-BENZONITRILO, ACIDO 4-[4-(2,3-DIHIDRO-BENZO[1,4]DIOXIN-6-IL)-5-PIRIDIN-2-IL-1H-IMIDAZOL-2-IL]-BENZAMIDA, 2-[4-BENZO[1,3]DIOXOL--5-IL-2-[4-(2H-TETRAZOL-5-IL)-FENIL]-1H-IMIDAZOL-5-IL}-PIRIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARAMCEUTICA. ESTOS COMPUESTOS SON INHIBIDORES DEL RECEPTOR 5 DE QUINASA DE TIPO ACTIVINA (ALK5) O UN INHIBIDOR DUAL ALK5/ALK4, POR LO QUE SON MODULADORES DE LA ACTIVIDAD DE MIOSTATINA, LOGRANDO ASI UNA DISMINUCION DEL TEJIDO GRASO Y UN CRECIMIENTO DEL TEJIDO MUSCULAR EN ANIMALES
PE2005000882A 2004-07-29 2005-07-27 Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina PE20060729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59235904P 2004-07-29 2004-07-29

Publications (1)

Publication Number Publication Date
PE20060729A1 true PE20060729A1 (es) 2006-08-12

Family

ID=35595039

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000882A PE20060729A1 (es) 2004-07-29 2005-07-27 Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina

Country Status (14)

Country Link
US (1) US20060194845A1 (es)
EP (1) EP1771171A1 (es)
JP (1) JP2008506787A (es)
CN (1) CN101031294A (es)
AR (1) AR050187A1 (es)
AU (1) AU2005280496B2 (es)
BR (1) BRPI0513914A (es)
CA (1) CA2576734C (es)
MX (1) MX2007001118A (es)
NO (1) NO20071113L (es)
PE (1) PE20060729A1 (es)
TW (1) TW200616621A (es)
WO (1) WO2006025988A1 (es)
ZA (1) ZA200700681B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008071605A2 (en) * 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
EP2152093A4 (en) * 2007-05-04 2011-05-25 Jana Pickova VERBUNDFUTTER FOR AQUACULTURES
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009047163A1 (en) * 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
CN101684457B (zh) * 2009-07-27 2013-01-09 中国科学院广州生物医药与健康研究院 I型转化生长因子受体抑制剂在产生诱导多能干细胞中的应用及其方法
AU2012240656A1 (en) * 2011-04-05 2013-10-24 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Compounds and methods for altering activin receptor-like kinase signalling
WO2013137832A1 (en) * 2012-03-16 2013-09-19 Nanyang Technological University Myostatin inhibitors
PL2880053T3 (pl) 2012-08-01 2021-01-11 Ikaika Therapeutics, Llc Łagodzenie uszkodzenia tkanek i włóknienia przez przeciwciało przeciwko ltbp4
WO2016025629A1 (en) 2014-08-12 2016-02-18 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
KR102434226B1 (ko) 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
BR112021011224A2 (pt) 2018-12-11 2021-08-24 Theravance Biopharma R&D Ip, Llc Inibidores de alk5
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder
JP2023502662A (ja) 2019-11-22 2023-01-25 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー Ａｌｋ５阻害剤としての置換１，５－ナフチリジンまたはキノリン
US20230414711A1 (en) * 2020-11-13 2023-12-28 The Jackson Laboratory Therapeutics targeting transforming growth factor beta family signaling

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
DE60027135T2 (de) * 1999-01-21 2007-01-11 Metamorphix, Inc. Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
EP1169317B1 (en) * 1999-04-09 2003-01-15 SmithKline Beecham Corporation Triarylimidazoles
GB0007405D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds

Also Published As

Publication number Publication date
CA2576734A1 (en) 2006-03-09
CN101031294A (zh) 2007-09-05
MX2007001118A (es) 2007-03-15
AR050187A1 (es) 2006-10-04
NO20071113L (no) 2007-02-27
WO2006025988A1 (en) 2006-03-09
JP2008506787A (ja) 2008-03-06
EP1771171A1 (en) 2007-04-11
TW200616621A (en) 2006-06-01
ZA200700681B (en) 2008-07-30
CA2576734C (en) 2010-03-16
US20060194845A1 (en) 2006-08-31
BRPI0513914A (pt) 2008-05-20
AU2005280496A1 (en) 2006-03-09
AU2005280496B2 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
PE20060729A1 (es) Compuestos heterociclicos como moduladores o inhibidores de la actividad de miostatina
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20070522A1 (es) 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo como inhibidor de dipeptidil peptidasa y composiciones farmaceuticas que lo contienen
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
ES2661444T3 (es) Nuevo derivado de nicotinamida o sal del mismo
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20080706A1 (es) Arilmidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
PE20070795A1 (es) Compuestos pirazol-urea-heterociclicos como inhibidores de cinasa
PE20040936A1 (es) Derivados de triazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
PE20120356A1 (es) Compuestos para el tratamiento de trastornos metabolicos
PE20050194A1 (es) Derivados de piridina-2-carboxamida como activadores de glucoquinasa
PE20091673A1 (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilizacion
PE20040987A1 (es) Nuevos compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
PE20120002A1 (es) Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
RU2008141509A (ru) Mglur5 модуляторы 1
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20090437A1 (es) Antagonistas no basicos del receptor de la hormona concentradora de melanina 1 y procedimientos
PE20060306A1 (es) Compuestos de heteroaril-amida sustituida
PE20090815A1 (es) Compuesto de amida
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20090150A1 (es) Compuestos derivados de oxadiazol
NZ609955A (en) Sgc stimulators
AR065850A1 (es) Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph
AR082458A1 (es) Combinacion que comprende un farmaco antipsicotico y un agonista de taar1

Legal Events

Date Code Title Description
FC Refusal